Sign In
Buy XNCR
$20.21
-1.28 (-5.96%)
At Close: Jul 31, 2026
Xencor Reports Third Quarter 2024 Financial Results
04:01pm, Wednesday, 06'th Nov 2024
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
07:00am, Monday, 04'th Nov 2024
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, toda
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?
10:56am, Friday, 01'st Nov 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 68.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positiv
Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Tuesday, 29'th Oct 2024
Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know
10:55am, Wednesday, 16'th Oct 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positiv
Xencor Announces Upcoming Change to Board of Directors
08:01am, Friday, 04'th Oct 2024
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, toda
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
04:01pm, Thursday, 12'th Sep 2024
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious
Xencor: Vudalimab Development Along With Hidden Gem Candidate
08:16am, Thursday, 12'th Sep 2024
Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prost
Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?
05:55am, Thursday, 12'th Sep 2024
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Xencor Stock Gains 23% on Encouraging Pipeline Advancements
01:25pm, Tuesday, 10'th Sep 2024
XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, toda
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
06:15pm, Monday, 05'th Aug 2024
Xencor (XNCR) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.37 per share a year ago.
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
08:01am, Thursday, 13'th Jun 2024
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, annou
Xencor Reports First Quarter 2024 Financial Results
04:09pm, Thursday, 09'th May 2024
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today
Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:01am, Monday, 06'th May 2024
Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
